Table 5.

Amount of Melan-A-specific TIL infused to patients

Patients	Total TIL (10−9)b	Melan-A specific TIL (10−6)c	Melan-A26–35 reactive lymphocytes (10−6)d
Melan-A/A2 specific TIL (n = 14)
RF-patients
M117	33.4	2,200	534
M182	3.7	740	252
M278 a	13.2	475	211
M134	22.5	450	270
M170a	9.5	190	38
M180a	9	180	54
M254 a	3.3	109	53
R-patients
M171	22	3,740	1,892
M199	8.3	556	108
M113	21.2	360	85
M263 a	12.6	315	101
M131	15.5	93	46
M204	26	52	26
M275a	9.2	37	28

^aMelanoma patients bearing only one invaded lymph node

^bTotal amount of TIL infused to patients

^cEstimated amount of Melan-A specific TIL infused (detected by tetramer labeling). Patients indicated in italics have been patients enrolled in the open study

^dEstimated amount of infused Melan-A_26–35 reactive lymphocytes (detected by IFN-γ intracellular labeling in response to peptide pulsed-T2 cells)